LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Listă Acțiuni・Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

Închisă

Sector Sănătate

75.43 0.23

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

74.8

Maxim

75.43

Indicatori cheie
By Trading Economics
Venit	-973K -16M
Vânzări	17M 161M
EPS	-0.16
Marjă de profit	-10.05
Angajați	610
EBITDA	-6.8M -28M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+27.93 upside

Dividende
By Dow Jones
Următoarele câștiguri	31 oct. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	-335M 7.1B
Deschiderea anterioară	75.2
Închiderea anterioară	75.43

Sentimentul știrilor

By Acuity

75%

25%

321 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

73 / 75.85 Suport & Rezistență

Intra-Cellular Therapies Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 sept. 2024, 01:45 UTC

Câștiguri

Preview -- Barron's

13 sept. 2024, 20:03 UTC

Top știri

Walgreens to Pay $106.8 Million Over Alleged Fraudulent Healthcare Billings

15 sept. 2024, 23:47 UTC

Market Talk

Gold Edges Higher Amid Mild Dollar Weakness -- Market Talk

15 sept. 2024, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2024, 23:03 UTC

Market Talk

Australian Bond Traders Watchful as Fed Easing Nears -- Market Talk

15 sept. 2024, 16:52 UTC

Top știri

Boeing Machinist Strike Adds Cash Crunch to New CEO's Rescue Mission -- WSJ

15 sept. 2024, 09:30 UTC

Top știri

Interest Rates Are Too High. The Fed Should Cut by a Half Point. -- WSJ

15 sept. 2024, 07:00 UTC

Top știri

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

14 sept. 2024, 14:09 UTC

Top știri

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- Update 1 -- WSJ

14 sept. 2024, 13:25 UTC

Top știri

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- WSJ

14 sept. 2024, 09:30 UTC

Top știri

Why a Fed Rate Cut Won't Solve the Housing Wealth Gap -- WSJ

14 sept. 2024, 09:30 UTC

Top știri

Americans Are Falling Behind on Their Bills. Wall Street Is Alarmed. -- WSJ

14 sept. 2024, 03:00 UTC

Top știri

What Scared Ford's CEO in China -- WSJ

14 sept. 2024, 03:00 UTC

Top știri

What Scared Ford's CEO in China -- WSJ -2-

14 sept. 2024, 00:01 UTC

Top știri

Why 96% of Boeing's Machinists Voted to Go on Strike -- Update

13 sept. 2024, 21:14 UTC

Top știri

Why 96% of Boeing's Machinists Voted to Go on Strike -- WSJ

13 sept. 2024, 21:06 UTC

Top știri

Starliner Astronauts Say NASA Ran Short of Time to Test Boeing Craft -- WSJ

13 sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

13 sept. 2024, 20:47 UTC

Market Talk

Saudi Arabia Credit Outlook Raised to Positive on Economic Investments -- Market Talk

13 sept. 2024, 20:44 UTC

Achiziții, Fuziuni, Preluări

Schlumberger Stock Was Once as Hot as Nvidia. Why It's a Buy. -- Barrons.com

13 sept. 2024, 20:41 UTC

Top știri

Berkshire Hathaway's Stock Is So Rich Even Berkshire Is Buying Less of It -- Update

13 sept. 2024, 20:31 UTC

Câștiguri

These Stocks Moved the Most Today: Adobe, Boeing, Trump Media, Oracle, Uber, RH, Moderna, Etsy, and More -- Barrons.com

13 sept. 2024, 20:13 UTC

Achiziții, Fuziuni, Preluări

BlackRock: Expects to Close Previously Announced Acquisition of Global Infrastructure Partners on Oct 1 >BLK

13 sept. 2024, 20:10 UTC

Achiziții, Fuziuni, Preluări

BlackRock Announces Expected Closing Date For Acquisition Of Global Infrastructure Partners >BLK

13 sept. 2024, 20:02 UTC

Achiziții, Fuziuni, Preluări

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept. 2024, 20:02 UTC

Achiziții, Fuziuni, Preluări

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept. 2024, 19:44 UTC

Market Talk

Treasury Yields Fall as Odds of 50bp Fed Cut Rise -- Market Talk

13 sept. 2024, 19:20 UTC

Market Talk

Crude-Oil Futures End Week With Small Gains -- Market Talk

13 sept. 2024, 19:09 UTC

Market Talk

U.S. Natural-Gas Futures Post Weekly Gain -- Market Talk

13 sept. 2024, 18:01 UTC

Market Talk

Gold Analysts Call For New Leg Of Rally -- Market Talk

Comparație

Modificare preț

Intra-Cellular Therapies Inc Așteptări

Obiectiv de preț

By TipRanks

27.93% sus

Prognoză pe 12 luni

Medie 96.43 USD 27.93%

Maxim 130 USD

Minim 74 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIntra-Cellular Therapies Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

15 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 15 analiști care au acordat evaluări ale acțiunilor Intra-Cellular Therapies Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

73 / 75.85Suport & Rezistență

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

321 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

EBITDA

Profit operațional

Despre Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is focused on the discovery, clinical development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company offers CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. Its lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. The Company also initiated its third monotherapy Phase III study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.